Blurbs

Analysts Offer Insights on Healthcare Companies: SQZ Biotechnologies (SQZ) and AVEO Pharma (AVEO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SQZ Biotechnologies (SQZResearch Report) and AVEO Pharma (AVEOResearch Report) with bullish sentiments.

SQZ Biotechnologies (SQZ)

Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on SQZ Biotechnologies today and set a price target of $42.00. The company’s shares closed last Tuesday at $3.20, close to its 52-week low of $2.73.

According to TipRanks.com, Cann is a 1-star analyst with an average return of -1.3% and a 39.8% success rate. Cann covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Syros Pharmaceuticals, and Intellia Therapeutics.

SQZ Biotechnologies has an analyst consensus of Strong Buy, with a price target consensus of $25.00.

See Insiders’ Hot Stocks on TipRanks >>

AVEO Pharma (AVEO)

JonesTrading analyst Soumit Roy reiterated a Buy rating on AVEO Pharma today and set a price target of $12.00. The company’s shares closed last Friday at $4.50.

According to TipRanks.com, Roy is a 3-star analyst with an average return of 2.9% and a 29.0% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Actinium Pharmaceuticals, and Monopar Therapeutics Inc.

AVEO Pharma has an analyst consensus of Strong Buy, with a price target consensus of $14.67, which is a 226.0% upside from current levels. In a report issued on June 8, H.C. Wainwright also maintained a Buy rating on the stock with a $19.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SQZ:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos